Last updated on August 2017

Management of Acute Stroke Patients on Treatment with New Oral Anticoagulants: Addressing Real-world Anticoagulant Management Issues in Stroke (ARAMIS) Registry”


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Stroke
  • Age: 18 Years
  • Gender: Male or Female

Inclusion Criteria

Patients are eligible to be included in the study if they meet the following criteria:
  1. Age 18 years or older
  2. Have been diagnosed with acute ischemic stroke and have been treated with dabigatran, rivaroxaban, apixaban, edoxaban within 7 days prior to admission, or
  3. Have been diagnosed with intracerebral hemorrhage and have been treated with warfarin or one of the new oral anticoagulants within 7 days prior to admission
  4. ARAMIS PRO follow-up study: Ability of patient or legally authorized representative to provide informed consent for longitudinal follow-up indicating they understand the purpose and the requirements of the study and are willing to participate.

Exclusion Criteria

  • Patients who were transferred from another hospital or discharged to other acute care facility will be excluded.

  • Recruitment Status: Open


    Brief Description Eligibility Contact Research Team


    Volunteer Sign-up

    Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.